| Viramune® Donation Programme
|
|
|
|
| |
Viramune® Donation Programme |
|
|
| |
Since 2000, Boehringer Ingelheim has given free access to single-dose Viramune® (nevirapine), to be used preferably in combination with other drugs, to prevent mother-to-child transmission (PMTCT) of the HI virus during birth. The programme acts as a catalyst for other organisations which benefit from the already developed infrastructure and also has the potential to reach out to more remote sites. An estimated number of 14,892 sites are already reached (status April 2008).
The free donation of Viramune® for mother and baby can be
applied for under: www.pmtctdonations.org. Furthermore the drug component is a substantial part of resources required for a comprehensive mother-to-child transmission (MTCT) prevention programme.
|
|
|
The company currently donates the product to 167 programmes in 59 countries in Africa, Asia, Latin America and Eastern Europe.
Boehringer Ingelheim sent the 1 millionth mother-child pair supply of Viramune® (nevirapine) to Malawi (status April 2008). 